Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Impact of routine cryptococcal antigen screening and targeted pre-emptive fluconazole therapy in antiretroviral naive HIV-infected adults with less than 100 CD4 cells/μL: a systematic review and meta-analysis.

Temfack E, Bigna JJ, Luma HN, Spijker R, Meintjes G, Jarvis JN, Dromer F, Harrison T, Cohen JF, Lortholary O.

Clin Infect Dis. 2018 Jul 18. doi: 10.1093/cid/ciy567. [Epub ahead of print]

PMID:
30020446
2.

Cryptococcal Antigen Screening in Asymptomatic HIV-Infected Antiretroviral Naïve Patients in Cameroon and Evaluation of the New Semi-Quantitative Biosynex CryptoPS Test.

Temfack E, Kouanfack C, Mossiang L, Loyse A, Fonkoua MC, Molloy SF, Koulla-Shiro S, Delaporte E, Dromer F, Harrison T, Lortholary O.

Front Microbiol. 2018 Mar 13;9:409. doi: 10.3389/fmicb.2018.00409. eCollection 2018.

3.

Cryptococcal Antigenemia in Immunocompromised Human Immunodeficiency Virus Patients in Rural Tanzania: A Preventable Cause of Early Mortality.

Letang E, Müller MC, Ntamatungiro AJ, Kimera N, Faini D, Furrer H, Battegay M, Tanner M, Hatz C, Boulware DR, Glass TR.

Open Forum Infect Dis. 2015 Apr 2;2(2):ofv046. doi: 10.1093/ofid/ofv046. eCollection 2015 Apr.

4.

Cryptococcal antigen screening by lay cadres using a rapid test at the point of care: A feasibility study in rural Lesotho.

Rick F, Niyibizi AA, Shroufi A, Onami K, Steele SJ, Kuleile M, Muleya I, Chiller T, Walker T, Van Cutsem G.

PLoS One. 2017 Sep 6;12(9):e0183656. doi: 10.1371/journal.pone.0183656. eCollection 2017.

5.

Six-month outcomes of HIV-infected patients given short-course fluconazole therapy for asymptomatic cryptococcal antigenemia.

Kapoor SW, Magambo KA, Kalluvya SE, Fitzgerald DW, Peck RN, Downs JA.

AIDS. 2015 Nov 28;29(18):2473-8. doi: 10.1097/QAD.0000000000000872.

6.

Estimated Prevalence of Cryptococcus Antigenemia (CrAg) among HIV-Infected Adults with Advanced Immunosuppression in Namibia Justifies Routine Screening and Preemptive Treatment.

Sawadogo S, Makumbi B, Purfield A, Ndjavera C, Mutandi G, Maher A, Kaindjee-Tjituka F, Kaplan JE, Park BJ, Lowrance DW.

PLoS One. 2016 Oct 19;11(10):e0161830. doi: 10.1371/journal.pone.0161830. eCollection 2016.

7.

Neurocognitive function in HIV-infected persons with asymptomatic cryptococcal antigenemia: a comparison of three prospective cohorts.

Montgomery MP, Nakasujja N, Morawski BM, Rajasingham R, Rhein J, Nalintya E, Williams DA, Huppler Hullsiek K, Kiragga A, Rolfes MA, Donahue Carlson R, Bahr NC, Birkenkamp KE, Manabe YC, Bohjanen PR, Kaplan JE, Kambugu A, Meya DB, Boulware DR; COAT and ORCAS Trial Teams.

BMC Neurol. 2017 Jun 12;17(1):110. doi: 10.1186/s12883-017-0878-2.

8.

Cost-effectiveness of serum cryptococcal antigen screening to prevent deaths among HIV-infected persons with a CD4+ cell count < or = 100 cells/microL who start HIV therapy in resource-limited settings.

Meya DB, Manabe YC, Castelnuovo B, Cook BA, Elbireer AM, Kambugu A, Kamya MR, Bohjanen PR, Boulware DR.

Clin Infect Dis. 2010 Aug 15;51(4):448-55. doi: 10.1086/655143.

9.

Asymptomatic cryptococcal antigen prevalence detected by lateral flow assay in hospitalised HIV-infected patients in São Paulo, Brazil.

Vidal JE, Toniolo C, Paulino A, Colombo A, Dos Anjos Martins M, da Silva Meira C, Pereira-Chioccola VL, Figueiredo-Mello C, Barros T, Duarte J, Fonseca F, Alves Cunha M, Mendes C, Ribero T, Dos Santos Lazera M, Rajasingham R, Boulware DR.

Trop Med Int Health. 2016 Dec;21(12):1539-1544. doi: 10.1111/tmi.12790. Epub 2016 Oct 24.

10.

Reflexive laboratory-based cryptococcal antigen screening and preemptive fluconazole therapy for cryptococcal antigenemia in HIV-infected individuals with CD4 <100 cells/µL: a stepped-wedge, cluster-randomized trial.

Meya DB, Kiragga AN, Nalintya E, Morawski BM, Rajasingham R, Park BJ, Mubiru A, Kaplan JE, Manabe YC, Boulware DR; ORCAS study team.

J Acquir Immune Defic Syndr. 2018 Nov 5. doi: 10.1097/QAI.0000000000001894. [Epub ahead of print]

PMID:
30399034
11.

Primary prophylaxis of cryptococcal disease with fluconazole in HIV-positive Ugandan adults: a double-blind, randomised, placebo-controlled trial.

Parkes-Ratanshi R, Wakeham K, Levin J, Namusoke D, Whitworth J, Coutinho A, Mugisha NK, Grosskurth H, Kamali A, Lalloo DG; Cryptococcal Trial Team.

Lancet Infect Dis. 2011 Dec;11(12):933-41. doi: 10.1016/S1473-3099(11)70245-6. Epub 2011 Oct 6.

12.

Long term 5-year survival of persons with cryptococcal meningitis or asymptomatic subclinical antigenemia in Uganda.

Butler EK, Boulware DR, Bohjanen PR, Meya DB.

PLoS One. 2012;7(12):e51291. doi: 10.1371/journal.pone.0051291. Epub 2012 Dec 10.

13.

Asymptomatic Cryptococcal Antigenemia in People Living with HIV (PLHIV) with Severe Immunosuppression: Is Routine CrAg Screening Indicated in India?

Anuradha S, H AN, Dewan R, Kaur R, Rajeshwari K.

J Assoc Physicians India. 2017 Apr;65(4):14-17.

PMID:
28527158
14.

Cost effectiveness of cryptococcal antigen screening as a strategy to prevent HIV-associated cryptococcal meningitis in South Africa.

Jarvis JN, Harrison TS, Lawn SD, Meintjes G, Wood R, Cleary S.

PLoS One. 2013 Jul 19;8(7):e69288. doi: 10.1371/journal.pone.0069288. Print 2013.

15.

Universal screening of Tanzanian HIV-infected adult inpatients with the serum cryptococcal antigen to improve diagnosis and reduce mortality: an operational study.

Wajanga BM, Kalluvya S, Downs JA, Johnson WD, Fitzgerald DW, Peck RN.

J Int AIDS Soc. 2011 Oct 11;14:48. doi: 10.1186/1758-2652-14-48.

16.

Cryptococcal Antigen Screening in Patients Initiating ART in South Africa: A Prospective Cohort Study.

Longley N, Jarvis JN, Meintjes G, Boulle A, Cross A, Kelly N, Govender NP, Bekker LG, Wood R, Harrison TS.

Clin Infect Dis. 2016 Mar 1;62(5):581-587. doi: 10.1093/cid/civ936. Epub 2015 Nov 12.

17.

Prevalence of cryptococcal infection among advanced HIV patients in Argentina using lateral flow immunoassay.

Frola C, Guelfand L, Blugerman G, Szyld E, Kaufman S, Cahn P, Sued O, Pérez H.

PLoS One. 2017 Jun 15;12(6):e0178721. doi: 10.1371/journal.pone.0178721. eCollection 2017.

18.

Cryptococcal antigen prevalence in HIV-infected Tanzanians: a cross-sectional study and evaluation of a point-of-care lateral flow assay.

Rugemalila J, Maro VP, Kapanda G, Ndaro AJ, Jarvis JN.

Trop Med Int Health. 2013 Sep;18(9):1075-1079. doi: 10.1111/tmi.12157.

19.

CD4 Cell Count Threshold for Cryptococcal Antigen Screening of HIV-Infected Individuals: A Systematic Review and Meta-analysis.

Ford N, Shubber Z, Jarvis JN, Chiller T, Greene G, Migone C, Vitoria M, Doherty M, Meintjes G.

Clin Infect Dis. 2018 Mar 4;66(suppl_2):S152-S159. doi: 10.1093/cid/cix1143.

20.

LATERAL FLOW ASSAY FOR CRYPTOCOCCAL ANTIGEN: AN IMPORTANT ADVANCE TO IMPROVE THE CONTINUUM OF HIV CARE AND REDUCE CRYPTOCOCCAL MENINGITIS-RELATED MORTALITY.

Vidal JE, Boulware DR.

Rev Inst Med Trop Sao Paulo. 2015 Sep;57 Suppl 19:38-45. doi: 10.1590/S0036-46652015000700008. Review.

Supplemental Content

Support Center